The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemiaLucy C. Fox, Andrew Grigg, Maciek Tatarczuch et al.|Blood Advances|2017Cited by 42
The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemiaAdrian Minson, Andrew Grigg, Katherine D. Cummins et al.|Blood Advances|2019Cited by 26
A Phase I study of ‘Tomudex’ and gemcitabine in advanced cancerC. Cripps, A. Abugaber, Gerald Batist et al.|European Journal of Cancer|1999Cited by 2